The CRCbiome study: a large prospective cohort study examining the role of lifestyle and the gut microbiome in colorectal cancer screening participants

Autor: Trine B. Rounge, Cecilie Bucher-Johannessen, Mingyang Song, Geir Hoff, Rikard Landberg, Harri Kangas, Scott J. Bultman, Thomas de Lange, Paula Berstad, Hege Salvesen Blix, Jan Inge Nordby, Kristin Ranheim Randel, Vahid Bemanian, Pekka Ellonen, Giske Ursin, Ane Sørlie Kværner, Edoardo Botteri, Einar Elvbakken Birkeland, Torbjørn Rognes, Eivind Hovig, Willem M. de Vos, Ole Herman Ambur, Anette Hjartåker, Elina Vinberg, Robert Lyle, Øyvind Holme, Erik Natvig
Přispěvatelé: Institute for Molecular Medicine Finland, Willem Meindert Vos de / Principal Investigator, de Vos & Salonen group, Research Programs Unit, HUMI - Human Microbiome Research
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
Cancer Research
Colorectal cancer
Colonoscopy
law.invention
Study Protocol
0302 clinical medicine
Randomized controlled trial
law
Prospective Studies
Prospective cohort study
Early Detection of Cancer
RC254-282
RISK
0303 health sciences
medicine.diagnostic_test
Norway
Incidence
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RANDOMIZED CONTROLLED-TRIAL
Advanced neoplasia
Middle Aged
Diets
Prognosis
3. Good health
Oncology
Occult Blood
030220 oncology & carcinogenesis
FOOD-FREQUENCY QUESTIONNAIRE
Screening
Biomarker (medicine)
Female
Colorectal Neoplasms
Adenoma
medicine.medical_specialty
3122 Cancers
Lifestyles
iFOBT
VALIDATION
03 medical and health sciences
Metagenomics sequencing
Internal medicine
Genetics
medicine
Humans
Fecal occult blood tests
Microbiome
Life Style
VLAG
Aged
030304 developmental biology
Gut microbiome
Prescription drugs
WIMEK
business.industry
MORTALITY
Cancer
BacGen
Sigmoidoscopy
FIT
Lifestyle
medicine.disease
Gastrointestinal Microbiome
Diet
ROC Curve
Case-Control Studies
Gut microbiomes
PATTERNS
FOLLOW-UP
SIGMOIDOSCOPY
business
Biomarkers
Follow-Up Studies
Zdroj: BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-14 (2021)
BMC Cancer, 21(1)
BMC Cancer 21 (2021) 1
ISSN: 1471-2407
Popis: BackgroundColorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary screening methods. To aid in the development of a non-invasive screening test with improved sensitivity and specificity, we have initiated a prospective biomarker study (CRCbiome), nested within a large randomized CRC screening trial in Norway. We aim to develop a microbiome-based classification algorithm to identify advanced colorectal lesions in screening participants testing positive for an immunochemical fecal occult blood test (FIT). We will also examine interactions with host factors, diet, lifestyle and prescription drugs. The prospective nature of the study also enables the analysis of changes in the gut microbiome following the removal of precancerous lesions.MethodsThe CRCbiome study recruits participants enrolled in the Bowel Cancer Screening in Norway (BCSN) study, a randomized trial initiated in 2012 comparing once-only sigmoidoscopy to repeated biennial FIT, where women and men aged 50–74 years at study entry are invited to participate. Since 2017, participants randomized to FIT screening with a positive test result have been invited to join the CRCbiome study. Self-reported diet, lifestyle and demographic data are collected prior to colonoscopy after the positive FIT-test (baseline). Screening data, including colonoscopy findings are obtained from the BCSN database. Fecal samples for gut microbiome analyses are collected both before and 2 and 12 months after colonoscopy. Samples are analyzed using metagenome sequencing, with taxonomy profiles, and gene and pathway content as primary measures. CRCbiome data will also be linked to national registries to obtain information on prescription histories and cancer relevant outcomes occurring during the 10 year follow-up period.DiscussionThe CRCbiome study will increase our understanding of how the gut microbiome, in combination with lifestyle and environmental factors, influences the early stages of colorectal carcinogenesis. This knowledge will be crucial to develop microbiome-based screening tools for CRC. By evaluating biomarker performance in a screening setting, using samples from the target population, the generalizability of the findings to future screening cohorts is likely to be high.Trial registrationClinicalTrials.govIdentifier:NCT01538550.
Databáze: OpenAIRE
Externí odkaz: